Skip to main contentSkip to navigation
Sirius Investors
Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc.

XBIO
NASDAQHealthcare

XBIO Earnings Reports, EPS & Revenue History

Quarterly EPS and revenue vs. estimates for Xenetic Biosciences, Inc.. Review beat/miss history, upcoming consensus figures, and earnings call transcripts when available.

EPS and Earnings Announcement

Latest Quarterly EPS
Next Earnings Announcement
Unlock for free

Already registered? Sign in

EPS vs. Estimates

Green band = beat vs estimate · Red band = miss · Lines show actual and consensus EPS.

Revenue vs. Estimates

Green band = revenue beat · Red band = revenue miss · Lines show reported vs consensus revenue.

EPS & Revenue vs. Estimates

Upgrade
DateEPS ActualEPS Est.EPS Diff.Revenue ActualRevenue Est.Revenue Diff.
Aug 7, 2026Upcoming
May 12, 2026
-0.20806.92K
Mar 12, 2026
-0.22-0.52+0.30766.30K690.00K+76.30K
Nov 12, 2025
-0.33-0.49+0.161.03M630.00K+396.96K
Aug 12, 2025
May 12, 2025
Mar 18, 2025
Nov 12, 2024
Aug 13, 2024
May 9, 2024
Mar 21, 2024
Nov 10, 2023
Aug 11, 2023
May 11, 2023
Mar 23, 2023
Nov 10, 2022
Aug 12, 2022
May 12, 2022
Mar 22, 2022
Nov 12, 2021
Aug 12, 2021
May 12, 2021
Mar 16, 2021
Nov 12, 2020
Aug 12, 2020
May 14, 2020
Mar 26, 2020
Nov 15, 2019
Aug 15, 2019
May 10, 2019
Mar 29, 2019
Nov 9, 2018
Aug 10, 2018
May 15, 2018
Mar 30, 2018
Nov 15, 2017
Aug 14, 2017
May 16, 2017
Apr 3, 2017
Nov 15, 2016
Aug 15, 2016
May 16, 2016
Mar 30, 2016
Nov 16, 2015
Aug 19, 2015
May 20, 2015
Apr 30, 2015
Nov 14, 2014
Aug 14, 2014
May 20, 2014
Apr 15, 2014
Nov 27, 2013
Jul 17, 2013
Apr 22, 2013
Jan 22, 2013
Dec 14, 2012
Jul 16, 2012
Apr 24, 2012
Nov 30, 2011

Earnings Call Transcripts

Upgrade

Earnings Call Transcripts Require Subscription

Access to earnings call transcripts and AI-powered summaries is available for Pro, Premium, and Enterprise subscribers.

View Pricing Plans

Revenue Breakdown

Want to understand XBIO's revenue sources? Explore detailed revenue breakdowns by product line and geographic region to see what's driving the company's top line.

View Revenue Breakdown